Analysts Set Expectations for GYRE Q3 Earnings

Gyre Therapeutics, Inc. (NASDAQ:GYRE) – Analysts at Noble Financial issued their Q3 2026 earnings estimates for shares of Gyre Therapeutics in a research report issued to clients and investors on Monday, August 10th. Noble Financial analyst R. Leboyer anticipates that the company will post earnings of ($0.10) per share for the quarter. The consensus estimate for Gyre Therapeutics’ current full-year earnings is ($0.30) per share. Noble Financial also issued estimates for Gyre Therapeutics’ Q4 2026 earnings at ($0.11) EPS.

Gyre Therapeutics (NASDAQ:GYRE) last released its quarterly earnings results on Friday, August 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Gyre Therapeutics had a negative net margin of 15.47% and a negative return on equity of 6.57%. The company had revenue of $29.11 million during the quarter, compared to analysts’ expectations of $26.49 million.

Other equities analysts also recently issued reports about the company. Wall Street Zen downgraded Gyre Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, May 16th. Weiss Ratings reissued a “sell (d-)” rating on shares of Gyre Therapeutics in a research report on Friday, August 7th. Finally, Zacks Research upgraded shares of Gyre Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, July 6th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, Gyre Therapeutics currently has a consensus rating of “Hold” and an average price target of $17.00.

Gyre Therapeutics Trading Up 2.5%

GYRE stock opened at $6.98 on Wednesday. The business’s fifty day moving average price is $6.35 and its 200 day moving average price is $7.00. Gyre Therapeutics has a 12-month low of $5.44 and a 12-month high of $9.42. The company has a market capitalization of $778.34 million, a PE ratio of -33.24 and a beta of 1.92.

Insiders Place Their Bets

In other Gyre Therapeutics news, COO Weiguo Ye sold 12,820 shares of the firm’s stock in a transaction on Thursday, May 21st. The stock was sold at an average price of $6.15, for a total value of $78,843.00. Following the sale, the chief operating officer directly owned 700,000 shares in the company, valued at $4,305,000. This trade represents a 1.80% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 9.50% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Gyre Therapeutics

Several hedge funds and other institutional investors have recently made changes to their positions in GYRE. Bank of America Corp DE grew its position in shares of Gyre Therapeutics by 28.8% in the 2nd quarter. Bank of America Corp DE now owns 6,277 shares of the company’s stock valued at $46,000 after buying an additional 1,402 shares during the last quarter. Alliancebernstein L.P. lifted its position in Gyre Therapeutics by 9.5% in the third quarter. Alliancebernstein L.P. now owns 21,830 shares of the company’s stock valued at $163,000 after acquiring an additional 1,900 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in Gyre Therapeutics by 4.7% in the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company’s stock valued at $301,000 after acquiring an additional 1,941 shares in the last quarter. JPMorgan Chase & Co. grew its holdings in shares of Gyre Therapeutics by 84.6% during the second quarter. JPMorgan Chase & Co. now owns 6,461 shares of the company’s stock worth $47,000 after purchasing an additional 2,961 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of Gyre Therapeutics by 77.8% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 7,413 shares of the company’s stock worth $54,000 after purchasing an additional 3,244 shares in the last quarter. Institutional investors and hedge funds own 23.99% of the company’s stock.

Gyre Therapeutics Company Profile

Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company’s proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.

Gyre’s preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer’s disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.